MADRIGAL PHARMACEUTICALS, INC. 8K

Madrigal Pharmaceuticals reported strong second-quarter 2026 Rezdiffra sales growth, expanded its resmetirom patent estate, initiated a Phase 1 trial of oral GLP-1 MGL-2086 for MASH combination therapy, and detailed higher expenses and a net loss alongside a solid cash position.

On July 30, 2026, Madrigal Pharmaceuticals, Inc. reported its second-quarter 2026 financial results and corporate updates, highlighting Rezdiffra (resmetirom) net sales of $364.3 million (71% year-over-year growth) with more than 49,000 patients on therapy as of June 30, 2026, the issuance of three new U.S. patents extending resmetirom-related intellectual property protection into the 2042–2045 timeframe, initiation of a Phase 1 single ascending dose trial of its oral GLP-1 candidate MGL-2086 as part of a planned Rezdiffra combination program in MASH, and a cash, cash equivalents, restricted cash and marketable securities balance of $838.9 million, alongside increased operating expenses leading to a quarterly net loss of $57.9 million and the announcement of an investor webcast to discuss these results and the company’s broader MASH-focused strategy.

Filing Facts

CIK

1157601

Ticker

MDGL

Form

8K

Source Type

fda

Accession

0001628280-26-050775

Alert Tier

6